Article

Pan-cancer survival modeling reveals structural limits of genomic feature integration in immunotherapy outcomes

2026-04-18

Abstract excerpt

<h4>Background</h4> Immune checkpoint inhibitors (ICIs) have improved outcomes across multiple cancer types, yet reliable predictors of survival remain limited. While genomic features such as tumor mutational burden (TMB) are widely used, their contribution to predictive modeling in heterogeneous real-world cohorts remains unclear. We evaluated the relative contributions of clinical and whole-genome sequencing (W...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4192f8ea-5d47-55cf-ba20-4b4effcf4430
DOI: 10.64898/2026.04.15.718634

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pan-cancer survival modeling reveals structural limits of genomic feature integration in immunotherapy outcomesDOI 10.64898/2026.04.15.718634Read

Is tumor mutational burden predictive of response to immunotherapy?Semantic proximity Read

Integrated germline and somatic features reveal divergent immune pathways driving ICB responseSemantic proximity Read

Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).Semantic proximity Read

Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity Read

Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity Read

Comprehensive analysis of prognosis markers with molecular features derived from pan-cancer whole-genome sequences.Semantic proximity Read

Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts.Semantic proximity Read

iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics dataSemantic proximity Read

Prognostic pan-cancer and single-cancer models: A large-scale analysis using a real-world clinico-genomic databaseSemantic proximity Read

Systematic identification of genomic non-response biomarkers to cancer therapiesSemantic proximity Read

Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’Semantic proximity Read

HINS: HLA-mediated immunogenic neoantigen score for robust prediction of immune checkpoint blockade responseSemantic proximity Read